Previous studies have shown the plausibility in treating colorectal cancer using MEK inhibitor combinations.42,43 With consideration of KRAS mutations in subpopulations having greater sensitivity to selumetinib, SEABED suggests that while the correct biomarker was used for the clinical trial, there may be other potential indications for selumetinib. This evidence concerns the gene MAP2K7 and colorectal cancer.